The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.

The company had posted a profit after tax of ₹55.83 crore in the corresponding quarter last fiscal year

Dizal grants AstraZeneca worldwide rights to develop and commercialise Zegfrovy Dizal will receive an upfront payment of $600M, and mileston...

AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending...

SAN MATEO, Calif., July 7, 2026 /PRNewswire/ -- Helix, the leading enterprise genomics company, today announced a multi-year relationship wi...

Good morning. AstraZeneca’s AI strategy has moved well past the exploration phase as upskilling employees became a priority.The biopharm...

The company has received permission to import for sale and distribution of Durvalumab solution for an additional indication

The UK based-pharmaceutical giant is transitioning to the market by delisting American Depositary Shares from the Nasdaq index.

AstraZeneca has unveiled a tie-up with China’s CSPC Pharmaceutical Group to ramp up development of experimental weight loss and diabetes dru...

AstraZeneca will license experimental drugs for ‌obesity and weight-related conditions from CSPC Pharmaceutical Group and collaborate on add...

The deal is the largest of Starmer’s visit to China as Britain seeks to strengthen ties

British pharmaceutical giant AstraZeneca has announced plans to invest $15 billion in China over the next seven years. The investment, aimed...

ROCKVILLE, Md. and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta"), a global clinical-stage biopharmaceutical com...

NATICK, Mass., Dec. 8, 2025 /PRNewswire/ -- Pillar Biosciences announced today an expansion of its existing laboratory access program with A...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a...